SCHEDULE: EcoR1 Capital Reduces Adaptimmune Stake Below 5%

EcoR1 Capital and its affiliates have reduced their beneficial ownership in Adaptimmune Therapeutics PLC to below 5% of the outstanding Ordinary Shares.

Summary

• EcoR1 Capital, LLC, Oleg Nodelman, and EcoR1 Capital Fund Qualified, L.P. have filed an Amendment No. 2 to their Schedule 13G regarding their beneficial ownership in Adaptimmune Therapeutics PLC.
• EcoR1 Capital, LLC and Oleg Nodelman each beneficially own 66,000,000 Ordinary Shares, representing 4.2% of the class.
• EcoR1 Capital Fund Qualified, L.P. beneficially owns 63,184,650 Ordinary Shares, representing 4.0% of the class.
• These Ordinary Shares are held through American Depositary Shares (ADSs), where each ADS represents 6 Ordinary Shares.
• The percentage ownership is calculated based on 1,590,309,546 Ordinary Shares outstanding as of August 11, 2025, as reported in the Issuer's Form 10-Q for the quarter ended June 30, 2025.
• The filing indicates that the reporting persons now hold 5 percent or less of the class, implying a reduction from a previous stake that was above 5%.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to a significant institutional investor reducing their stake below the 5% threshold, which can be perceived as a loss of confidence or a strategic divestment.

Negatives

• A significant institutional investor, EcoR1 Capital, has reduced its beneficial ownership in Adaptimmune Therapeutics PLC to below the 5% threshold, which could be interpreted as a decrease in confidence or a strategic portfolio adjustment.

Risks

• The reduction in stake by a notable institutional investor could signal potential concerns about the company's future performance or valuation, potentially leading to negative market sentiment.

Future Outlook

NA

Industry Context

This filing reflects a change in a significant institutional investor's position within the biotechnology or pharmaceutical sector, where investor confidence and strategic shifts can influence company valuations. Such changes are closely watched by the market as indicators of investor sentiment towards specific companies or the broader industry.

Stakeholder Impact

• Shareholders may view the reduction in stake by a significant institutional investor as a bearish signal, potentially impacting share price.
• Investment professionals may re-evaluate their positions or analysis of Adaptimmune Therapeutics PLC based on this change in institutional ownership.

Key Dates

Recommendation

While a significant investor reducing their stake can be a negative signal, this filing is a disclosure of a past event and does not provide new operational or financial data. Investors should hold and monitor future company performance and other institutional ownership changes, as this single event, while notable, may not warrant an immediate sell decision without further context.

Keywords

Adaptimmune Therapeutics PLC, EcoR1 Capital, Beneficial Ownership, Schedule 13G, SEC Filing, Ordinary Shares, American Depositary Shares, Institutional Investor